FDA approves first PI3K inhibitor for breast cancer |
Clinical News
eMediNexus Coverage from: 
FDA approves first PI3K inhibitor for breast cancer
eMediNexus,  27 May 2019
remove_red_eye 568 Views
#Hematology #Obstetrics and Gynecology #Oncology #Pathology and Lab Medicine #Pharmacist

0 Read Comments                

The U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer (as detected by an FDA-approved test) following progression on or after an endocrine-based regimen.

The FDA also approved the companion diagnostic test, therascreen PIK3CA RGQ PCR Kit, to detect the PIK3CA mutation in a tissue and/or a liquid biopsy. Patients who are negative by the therascreen test using the liquid biopsy should undergo tumor biopsy for PIK3CA mutation testing. (FDA, May 24, 2019)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now